Statins: the workhorse of cardiovascular prevention

If you wanted to design the cleanest possible experiment in medicine, you’d want a drug with a clear mechanism, a dose-response you can read off a graph, and a body count of trials so large that chance stops being a plausible explanation. Statins are that drug. They inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis; the liver responds by pulling more LDL out of the blood; LDL falls; and cardiovascular events fall in near-linear proportion to how far the LDL drops. The Cholesterol Treatment Trialists’ (CTT) collaboration — pooling individual data from roughly 170,000 people — put a number on it: about a 21% reduction in major vascular events for every ~1 mmol/L (39 mg/dL) fall in LDL, and that benefit compounds with each year you stay on treatment.

So why is this a “context” entry and not a flat “do”? Because a statin is not something you take because it’s healthy in the abstract. It’s a prescription that pays off in proportion to your absolute risk — and whether your risk is high enough to bother is exactly the judgment that belongs to you and a clinician, not to a supplement stack.

What the evidence actually shows

The strongest case is secondary prevention — people who already have cardiovascular disease. Here the absolute risk is high, so the relative risk reduction translates into large, concrete benefit: fewer heart attacks, fewer strokes, fewer deaths. Guidelines like the 2018 AHA/ACC cholesterol guideline recommend high-intensity statins as first-line for this group, and the argument is close to unanswerable.

Primary prevention — people without established disease — is more nuanced, not because statins stop working (they don’t; the CTT dose-response holds across risk levels), but because the absolute benefit shrinks as baseline risk falls. Treating a low-risk 40-year-old prevents very few events per hundred people treated; treating a high-risk 65-year-old prevents many. This is why risk calculators exist and why the honest answer to “should I be on one?” is genuinely individual.

The muscle-symptom story

Statins have a reputation for causing muscle aches, and it deters a lot of people. The reputation is mostly — not entirely — a nocebo effect. In SAMSON, an elegant blinded n-of-1 trial, patients who’d previously quit statins for side effects cycled through months of statin, placebo, and nothing. The result: symptom burden on placebo months was about 90% of that on statin months. The aches were real experiences, but the pill mostly wasn’t causing them. True statin-associated myopathy exists and rare severe reactions (rhabdomyolysis) are a genuine, monitorable risk — but the everyday “statins make me sore” is, for most people, not the drug. That’s worth knowing before you rule the class out.

The diabetes signal, in proportion

Statins do modestly raise the risk of new-onset type 2 diabetes — the Sattar meta-analysis found about a 9% relative increase, which works out to roughly one extra diagnosis per 255 people treated for four years. This is real and shouldn’t be waved away. But it needs to be held next to the benefit: in anyone with a genuine indication, the cardiovascular events prevented vastly outnumber the diabetes cases caused, and the effect is concentrated in people already near the diabetes threshold. It’s a reason for a clinician to watch glucose, not a reason to avoid a drug that prevents heart attacks.

The honest bottom line

Statins are cheap, generic, deeply studied, and — once you strip out the nocebo noise — better tolerated than their reputation. If you have cardiovascular disease, the case is strong enough that “context” understates it. If you’re doing primary prevention, the question is really “what’s my absolute risk, and does moving it justify a lifelong daily pill?” — a question with a real answer, but one that depends on your numbers. Bring your LDL, your ApoB if you have it, and your risk profile to a clinician and have the conversation without either the fear-mongering or the reflexive resistance. This is one of the few places in this guide where the evidence is unambiguous; the only genuine uncertainty is whether you are the person it’s for.